JeansLab Signs Official Dealership Agreement with Switzerland's "Infeco"

Securing Rights for Domestic Supply and Technical Support of 'TLA Solutions'

JeansLab, a subsidiary of GC specializing in molecular diagnostic solutions, announced on October 28 that it has signed an official dealership agreement with Infeco, a global laboratory automation company based in Switzerland.

(From left) Ricardo Triunfo, CEO of Infeco, and Byungho Woo, CEO of JeansLab, are posing for a commemorative photo after signing the official dealership contract. JeansLab

Through this agreement, JeansLab has secured the rights to supply and provide technical support for Infeco's advanced fully automated testing systems, ProTube and FlexLab (TLA) solutions, in South Korea. JeansLab has already established and is stably operating Infeco's largest TLA system in Asia at the GC Medical Foundation.

This system is capable of processing the highest number of specimens per hour in the Asia-Pacific region and ranks among the top 10 globally in terms of total track length and the scale of connected analytical equipment. This achievement is regarded as a significant advancement in the automation level of diagnostic testing in South Korea.

Byungho Woo, CEO of JeansLab, stated, "By formalizing our dealership partnership with Infeco and leveraging the proven technological capabilities demonstrated through the GC Medical Foundation project, we will accelerate the expansion of the domestic laboratory automation market. We aim to set a new standard for laboratory automation in South Korea through customized services and continuous investment in technology."

Ricardo Triunfo, CEO of Infeco, commented, "South Korea is a leading medical market in Asia, and we are very pleased to introduce our innovative automation solutions through this collaboration. Infeco's open connectivity technology will contribute to enhancing the efficiency and accuracy of clinical laboratories, and our partnership with JeansLab will serve as a key opportunity to establish a long-term growth foundation in the Korean market."